JP2020528461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528461A5 JP2020528461A5 JP2020526688A JP2020526688A JP2020528461A5 JP 2020528461 A5 JP2020528461 A5 JP 2020528461A5 JP 2020526688 A JP2020526688 A JP 2020526688A JP 2020526688 A JP2020526688 A JP 2020526688A JP 2020528461 A5 JP2020528461 A5 JP 2020528461A5
- Authority
- JP
- Japan
- Prior art keywords
- oligo
- bond
- bonds
- conjugate
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 239000004202 carbamide Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 230000002285 radioactive effect Effects 0.000 claims 8
- 150000001768 cations Chemical class 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 5
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- ABTOQLMXBSRXSM-UHFFFAOYSA-N silicon tetrafluoride Chemical compound F[Si](F)(F)F ABTOQLMXBSRXSM-UHFFFAOYSA-N 0.000 claims 4
- SYFGLWDDLZQFNI-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1,4,8,11-tetrazabicyclo[6.6.2]hexadecan-11-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCCN2CCN(CC(=O)O)CCCN1CC2 SYFGLWDDLZQFNI-UHFFFAOYSA-N 0.000 claims 3
- 239000007983 Tris buffer Substances 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- GSRZVAGTAJGFRZ-UHFFFAOYSA-N 6-hydrazinyl-n-methylpyridine-3-carboxamide Chemical compound CNC(=O)C1=CC=C(NN)N=C1 GSRZVAGTAJGFRZ-UHFFFAOYSA-N 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000012216 imaging agent Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229920002601 oligoester Polymers 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 229960003330 pentetic acid Drugs 0.000 claims 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 229910052710 silicon Inorganic materials 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 claims 1
- KIUIVKNVSSLOAG-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotridecan-11-one Chemical compound O=C1CCNCCNCCNCCN1 KIUIVKNVSSLOAG-UHFFFAOYSA-N 0.000 claims 1
- -1 1-carboxy-3-carboxypropyl Chemical group 0.000 claims 1
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 claims 1
- RPNMGUBLKCLAEK-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanyl-n,n-diethylethanamine;hydrochloride Chemical compound [Cl-].CC[NH+](CC)CCSC1=CC=C(Cl)C=C1 RPNMGUBLKCLAEK-UHFFFAOYSA-N 0.000 claims 1
- FHQWIXXRHHMBQL-UHFFFAOYSA-N 2-[1,3,10-tris(carboxymethyl)-1,3,6,10-tetrazacyclododec-6-yl]acetic acid Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CN(CC(O)=O)CC1 FHQWIXXRHHMBQL-UHFFFAOYSA-N 0.000 claims 1
- GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 claims 1
- SQKUFYLUXROIFM-UHFFFAOYSA-N 2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC=2C(=C(C)N=CC=2COP(O)(O)=O)O)CC(O)=O)=C1O SQKUFYLUXROIFM-UHFFFAOYSA-N 0.000 claims 1
- DZTVAULYUGBHSF-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 DZTVAULYUGBHSF-UHFFFAOYSA-N 0.000 claims 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- XSNFRUQUGNIDGC-UHFFFAOYSA-N CN(C=CC(CC(N)=O)=C1O)C1=O Chemical compound CN(C=CC(CC(N)=O)=C1O)C1=O XSNFRUQUGNIDGC-UHFFFAOYSA-N 0.000 claims 1
- 101100243399 Caenorhabditis elegans pept-2 gene Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- LSFODDNIDIWZCJ-UHFFFAOYSA-N OC(=O)CN1CCN(CC(O)=O)CCN(Cc2ccc(cc2)[N+]([O-])=O)N(CC(O)=O)CC1 Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(Cc2ccc(cc2)[N+]([O-])=O)N(CC(O)=O)CC1 LSFODDNIDIWZCJ-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 claims 1
- CYJYKTMBMMYRHR-UHFFFAOYSA-N acetic acid;1,4,7-triazonane Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.C1CNCCNCCN1 CYJYKTMBMMYRHR-UHFFFAOYSA-N 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022065524A JP2022101601A (ja) | 2017-07-28 | 2022-04-12 | デュアルモードの放射性トレーサーおよび療法剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17183795.8 | 2017-07-28 | ||
| EP17183795 | 2017-07-28 | ||
| PCT/EP2018/070533 WO2019020831A1 (en) | 2017-07-28 | 2018-07-30 | AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065524A Division JP2022101601A (ja) | 2017-07-28 | 2022-04-12 | デュアルモードの放射性トレーサーおよび療法剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528461A JP2020528461A (ja) | 2020-09-24 |
| JP2020528461A5 true JP2020528461A5 (enExample) | 2021-04-01 |
| JP7059372B2 JP7059372B2 (ja) | 2022-04-25 |
Family
ID=59501286
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526688A Active JP7059372B2 (ja) | 2017-07-28 | 2018-07-30 | デュアルモードの放射性トレーサーおよび療法剤 |
| JP2022065524A Pending JP2022101601A (ja) | 2017-07-28 | 2022-04-12 | デュアルモードの放射性トレーサーおよび療法剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065524A Pending JP2022101601A (ja) | 2017-07-28 | 2022-04-12 | デュアルモードの放射性トレーサーおよび療法剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11413360B2 (enExample) |
| EP (3) | EP4424378A3 (enExample) |
| JP (2) | JP7059372B2 (enExample) |
| KR (2) | KR20240027896A (enExample) |
| CN (1) | CN111132700B (enExample) |
| AU (2) | AU2018308699B2 (enExample) |
| BR (1) | BR112020001785A2 (enExample) |
| CA (1) | CA3071315A1 (enExample) |
| DK (1) | DK3658194T3 (enExample) |
| EA (1) | EA202090370A1 (enExample) |
| ES (1) | ES3011272T3 (enExample) |
| FI (1) | FI3658194T3 (enExample) |
| HU (1) | HUE070098T2 (enExample) |
| IL (2) | IL272291B2 (enExample) |
| MX (2) | MX2020000352A (enExample) |
| PL (1) | PL3658194T3 (enExample) |
| PT (1) | PT3658194T (enExample) |
| SG (1) | SG11202000725WA (enExample) |
| WO (1) | WO2019020831A1 (enExample) |
| ZA (1) | ZA202000467B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240027896A (ko) | 2017-07-28 | 2024-03-04 | 테크니쉐 우니베르지테트 뮌헨 | 이중 모드 방사성 트레이서 및 치료법 |
| BR112021012110A2 (pt) * | 2019-01-30 | 2021-09-08 | Technische Universität München | Radiofarmacêuticos substituídos por aceptor de fluoreto de silício |
| WO2020157177A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
| CA3128406A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universitat Munchen | Cancer diagnostic imaging agents |
| CN112168978B (zh) * | 2019-07-03 | 2022-01-11 | 北京大学 | 一种抗体偶联药物及其药物组合物与应用 |
| EP4041213A4 (en) * | 2019-10-29 | 2023-12-27 | The Cleveland Clinic Foundation | Psma-targeting imaging agents |
| CN113350531A (zh) * | 2020-03-02 | 2021-09-07 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| GB202005282D0 (en) * | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
| EP4185336A1 (en) | 2020-07-23 | 2023-05-31 | Technische Universität München | Silicon-containing ligand compounds |
| KR20230066382A (ko) | 2020-09-03 | 2023-05-15 | 큐리엄 유에스 엘엘씨 | 64Cu-DOTATATE의 스케일 업을 위한 방사성표지 및 제형 |
| EP4023250A1 (en) * | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| IL305134A (en) * | 2021-02-15 | 2023-10-01 | Technische Universit?T M?Nchen | Dual mode radio and medical tracker |
| CA3215723A1 (en) * | 2021-04-02 | 2022-10-06 | Advanced Accelerator Applications | Diagnostic methods of prostate cancer |
| JP2024517971A (ja) * | 2021-05-14 | 2024-04-23 | テクニシェ ユニバーシタット ミュンヘン | 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体 |
| GB202108779D0 (en) | 2021-06-18 | 2021-08-04 | Blue Earth Diagnostics Ltd | Si-at therapeutic/diagnostic compounds |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| US20250313579A1 (en) * | 2021-08-05 | 2025-10-09 | Technische Universität München | Ligand compounds comprising a chelating group as a bridging group |
| GB202113646D0 (en) | 2021-09-24 | 2021-11-10 | Blue Earth Diagnostics Ltd | Method of preparation of 18F labelled silyl-fluoride compounds |
| CN114671806B (zh) * | 2022-04-08 | 2024-03-01 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
| GB202207372D0 (en) | 2022-05-19 | 2022-07-06 | Blue Earth Diagnostics Ltd | Synthesis of fluorosilyl compounds |
| JP2025525111A (ja) | 2022-07-29 | 2025-08-01 | テクニシェ ユニバーシタット ミュンヘン | 放射性医薬品のためのケイ素系フッ化物アクセプター基 |
| WO2024054226A1 (en) * | 2022-09-06 | 2024-03-14 | Hoang Ba Xuan | Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment |
| CA3264385A1 (en) * | 2022-09-20 | 2024-03-28 | Universität Augsburg | NEW MINIGASTRINE-DERIVED CHOLECYSTOKIN 2 RECEPTOR-BINDING MOLECULES FOR TARGETED IMAGING AND RADIOTHERAPY |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| IL319722A (en) | 2022-09-23 | 2025-05-01 | Nuclidium Ag | High purity radionuclides and their diagnostic and medical uses |
| CN120417945A (zh) * | 2022-11-14 | 2025-08-01 | 阿克提斯肿瘤学公司 | 肾脏中小蛋白滞留的减少 |
| KR20260085122A (ko) | 2023-09-29 | 2026-06-08 | 악티스 온콜로지, 인크. | 미니단백질, 접합체 및 이의 용도 |
| GB202316239D0 (en) | 2023-10-24 | 2023-12-06 | Blue Earth Diagnostics Ltd | Therapeutic combination |
| WO2025250644A1 (en) * | 2024-05-28 | 2025-12-04 | Case Western Reserve University | Fluorescent nuclide-containing agents for detecting and treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7384394A (en) * | 1993-06-30 | 1995-01-24 | Akzo Nobel N.V. | Chelating compounds |
| EP1420831A1 (en) * | 2001-07-27 | 2004-05-26 | Targesome, Inc. | Lipid constructs as therapeutic and imaging agents |
| CN102626522B (zh) * | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| CA2949936C (en) * | 2014-06-10 | 2022-10-18 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP3209336B1 (en) | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US20160287730A1 (en) * | 2015-03-31 | 2016-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Labeled evans blue dye derivative for in vivo serum albumin labeling |
| EP3303349B1 (en) * | 2015-05-26 | 2022-07-06 | The Regents of the University of California | Novel heteroaromatic silicon-fluoride-acceptors useful for 18f labeling of molecules and biomolecules, and methods of preparing same |
| KR20240027896A (ko) | 2017-07-28 | 2024-03-04 | 테크니쉐 우니베르지테트 뮌헨 | 이중 모드 방사성 트레이서 및 치료법 |
| DK3723815T3 (da) * | 2017-12-11 | 2022-07-11 | Univ Muenchen Tech | PSMA ligander til billeddannelse og endoradioterapi |
| CA3128406A1 (en) | 2019-01-30 | 2020-08-06 | Technische Universitat Munchen | Cancer diagnostic imaging agents |
| WO2020157177A1 (en) | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
-
2018
- 2018-07-30 KR KR1020247006169A patent/KR20240027896A/ko active Pending
- 2018-07-30 IL IL272291A patent/IL272291B2/en unknown
- 2018-07-30 CA CA3071315A patent/CA3071315A1/en active Pending
- 2018-07-30 SG SG11202000725WA patent/SG11202000725WA/en unknown
- 2018-07-30 AU AU2018308699A patent/AU2018308699B2/en active Active
- 2018-07-30 US US16/634,759 patent/US11413360B2/en active Active
- 2018-07-30 PT PT187435409T patent/PT3658194T/pt unknown
- 2018-07-30 BR BR112020001785-0A patent/BR112020001785A2/pt unknown
- 2018-07-30 MX MX2020000352A patent/MX2020000352A/es unknown
- 2018-07-30 ES ES18743540T patent/ES3011272T3/es active Active
- 2018-07-30 CN CN201880062949.0A patent/CN111132700B/zh active Active
- 2018-07-30 DK DK18743540.9T patent/DK3658194T3/da active
- 2018-07-30 FI FIEP18743540.9T patent/FI3658194T3/fi active
- 2018-07-30 IL IL318092A patent/IL318092A/en unknown
- 2018-07-30 HU HUE18743540A patent/HUE070098T2/hu unknown
- 2018-07-30 KR KR1020207005589A patent/KR102752620B1/ko active Active
- 2018-07-30 EP EP24184312.7A patent/EP4424378A3/en active Pending
- 2018-07-30 EP EP18743540.9A patent/EP3658194B1/en active Active
- 2018-07-30 PL PL18743540.9T patent/PL3658194T3/pl unknown
- 2018-07-30 JP JP2020526688A patent/JP7059372B2/ja active Active
- 2018-07-30 EA EA202090370A patent/EA202090370A1/ru unknown
- 2018-07-30 WO PCT/EP2018/070533 patent/WO2019020831A1/en not_active Ceased
- 2018-07-30 EP EP22150556.3A patent/EP4000640A1/en not_active Withdrawn
-
2020
- 2020-01-10 MX MX2023007914A patent/MX2023007914A/es unknown
- 2020-01-23 ZA ZA2020/00467A patent/ZA202000467B/en unknown
-
2022
- 2022-04-12 JP JP2022065524A patent/JP2022101601A/ja active Pending
- 2022-06-24 US US17/849,297 patent/US12390540B2/en active Active
-
2024
- 2024-01-24 AU AU2024200440A patent/AU2024200440B2/en active Active
- 2024-11-15 US US18/948,808 patent/US12453787B2/en active Active
-
2025
- 2025-09-24 US US19/338,850 patent/US20260021211A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024529307A5 (enExample) | ||
| CA2225453C (en) | Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis | |
| JP2024514528A5 (enExample) | ||
| AU2018308699A1 (en) | Dual mode radiotracer and -therapeutics | |
| RU2019139432A (ru) | Фармакокинетическая оптимизация бифункциональных хелатов и их применение | |
| JP2022509220A5 (ja) | 腫瘍抗原標的化剤、医薬組成物、癌診断薬又は癌治療薬、ｉｎ ｖｉｔｒｏ法、及びその化合物 | |
| WO2020157184A1 (en) | Cancer diagnostic imaging agents | |
| RU2017114360A (ru) | Радиофармацевтический конъюгат | |
| HRP20241453T1 (hr) | Psma ligandi za snimanje i endoradioterapiju | |
| US12427207B2 (en) | Pharmaceutical formulations | |
| JP2024536362A5 (enExample) | ||
| JP2018523671A5 (enExample) | ||
| US20250375544A1 (en) | Dual mode radiotracer and -therapeutics | |
| Urbanovsky et al. | Lanthanide complexes of DO3A–(Dibenzylamino) methylphosphinate: effect of Protonation of the Dibenzylamino Group on the water-exchange rate and the binding of human serum albumin | |
| JP2024510267A5 (enExample) | ||
| JP2025524769A5 (enExample) | ||
| IL305134A (en) | Dual mode radio and medical tracker | |
| JP2024517971A5 (enExample) | ||
| EA050309B1 (ru) | Фармацевтические составы | |
| WO2025087896A1 (en) | Therapeutic combination | |
| RU2024127322A (ru) | Соединения и радиолиганды для нацеливания на рецептор нейротензина и их применение | |
| NZ763033B2 (en) | Psma ligands for imaging and endoradiotherapy | |
| HK1248585A1 (en) | Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents |